A phase IIa open-label, multi-centre study of TP300 as a single agent as first line therapy in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. EuraCT number 2009-012097-12

  • Ford, Daniel (Principal Investigator)

Project Details

Short titleA phase IIa open-label, multi-centre study of TP300 as a single agent as first line therapy in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. EuraCT number 2009-012097-12
StatusFinished
Effective start/end date1/10/09 → 3/03/11

Funding

  • Sandwell & West Birmingham Hospitals